176.93
price up icon1.97%   3.41
after-market After Hours: 177.16 0.23 +0.13%
loading
Biogen Inc stock is traded at $176.93, with a volume of 2.46M. It is up +1.97% in the last 24 hours and down -4.71% over the past month. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$173.52
Open:
$172.71
24h Volume:
2.46M
Relative Volume:
2.30
Market Cap:
$25.77B
Revenue:
$9.67B
Net Income/Loss:
$1.16B
P/E Ratio:
9.6315
EPS:
18.37
Net Cash Flow:
$1.47B
1W Performance:
-3.56%
1M Performance:
-4.71%
6M Performance:
-18.66%
1Y Performance:
-29.09%
1-Day Range:
Value
$170.72
$177.25
1-Week Range:
Value
$170.71
$185.00
52-Week Range:
Value
$170.71
$268.30

Biogen Inc Stock (BIIB) Company Profile

Name
Name
Biogen Inc
Name
Phone
(781) 464-2000
Name
Address
225 BINNEY STREET, CAMBRIDGE, MA
Name
Employee
7,570
Name
Twitter
@biogen
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
BIIB's Discussions on Twitter

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-24 Reiterated Needham Buy
Feb-14-24 Downgrade Wells Fargo Overweight → Equal Weight
Jan-24-24 Downgrade UBS Buy → Neutral
Dec-20-23 Resumed Cantor Fitzgerald Overweight
Dec-07-23 Upgrade Raymond James Mkt Perform → Outperform
Sep-06-23 Initiated HSBC Securities Buy
Jul-27-23 Initiated Scotiabank Sector Outperform
Jul-24-23 Reiterated UBS Buy
May-01-23 Upgrade Guggenheim Neutral → Buy
Apr-17-23 Upgrade Piper Sandler Neutral → Overweight
Oct-26-22 Upgrade Goldman Neutral → Buy
Oct-13-22 Upgrade Stifel Hold → Buy
Oct-07-22 Upgrade Argus Hold → Buy
Sep-28-22 Upgrade BMO Capital Markets Market Perform → Outperform
Sep-28-22 Upgrade Mizuho Neutral → Buy
Sep-28-22 Upgrade Robert W. Baird Neutral → Outperform
Apr-18-22 Upgrade Wells Fargo Equal Weight → Overweight
Mar-08-22 Downgrade Stifel Buy → Hold
Mar-03-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-04-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-04-22 Reiterated Barclays Equal Weight
Feb-04-22 Reiterated BofA Securities Neutral
Feb-04-22 Reiterated Cowen Outperform
Feb-04-22 Reiterated Morgan Stanley Overweight
Feb-04-22 Reiterated Needham Buy
Feb-04-22 Reiterated Oppenheimer Outperform
Feb-04-22 Reiterated RBC Capital Mkts Sector Perform
Feb-04-22 Reiterated Robert W. Baird Neutral
Feb-04-22 Reiterated Wedbush Neutral
Feb-04-22 Reiterated Wells Fargo Equal Weight
Feb-04-22 Reiterated Wolfe Research Peer Perform
Jan-13-22 Downgrade Guggenheim Buy → Neutral
Jan-12-22 Downgrade Piper Sandler Overweight → Neutral
Dec-10-21 Resumed Raymond James Mkt Perform
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Initiated BMO Capital Markets Outperform
Sep-23-21 Initiated Needham Buy
Jun-18-21 Upgrade Piper Sandler Neutral → Overweight
Jun-14-21 Reiterated Truist Buy
Jun-11-21 Upgrade Bernstein Mkt Perform → Outperform
Jun-10-21 Upgrade UBS Neutral → Buy
Jun-08-21 Upgrade Atlantic Equities Underweight → Neutral
Jun-08-21 Reiterated Barclays Equal Weight
Jun-08-21 Upgrade Citigroup Sell → Neutral
Jun-08-21 Reiterated H.C. Wainwright Buy
Jun-08-21 Reiterated Jefferies Buy
Jun-08-21 Reiterated Morgan Stanley Overweight
Jun-08-21 Reiterated RBC Capital Mkts Sector Perform
Jun-08-21 Upgrade Robert W. Baird Underperform → Neutral
Jun-08-21 Reiterated Stifel Buy
Jun-08-21 Upgrade William Blair Mkt Perform → Outperform
Jun-07-21 Upgrade BofA Securities Underperform → Neutral
Jun-07-21 Upgrade Cowen Market Perform → Outperform
Jun-07-21 Upgrade Raymond James Underperform → Mkt Perform
Feb-05-21 Downgrade DZ Bank Buy → Hold
Jan-29-21 Upgrade Stifel Hold → Buy
Nov-10-20 Upgrade DZ Bank Hold → Buy
Nov-09-20 Downgrade Atlantic Equities Neutral → Underweight
Nov-09-20 Downgrade BofA Securities Neutral → Underperform
Nov-09-20 Downgrade Cowen Outperform → Market Perform
Nov-09-20 Reiterated H.C. Wainwright Buy
Nov-04-20 Upgrade BofA Securities Underperform → Neutral
Nov-04-20 Upgrade Jefferies Hold → Buy
Nov-04-20 Upgrade Wells Fargo Equal Weight → Overweight
Oct-28-20 Initiated UBS Neutral
Jul-27-20 Upgrade Morgan Stanley Underweight → Overweight
Jun-22-20 Downgrade Barclays Overweight → Equal Weight
Jun-22-20 Reiterated RBC Capital Mkts Sector Perform
Jun-09-20 Downgrade Bernstein Outperform → Mkt Perform
Apr-23-20 Downgrade Citigroup Neutral → Sell
Apr-23-20 Downgrade Raymond James Mkt Perform → Underperform
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Jan-27-20 Upgrade Canaccord Genuity Hold → Buy
Dec-13-19 Upgrade Credit Suisse Underperform → Neutral
Dec-02-19 Downgrade Robert W. Baird Neutral → Underperform
View All

Biogen Inc Stock (BIIB) Latest News

pulisher
09:33 AM

Biogen's SWOT analysis: stock outlook amid pipeline challenges, market shifts - Investing.com

09:33 AM
pulisher
04:12 AM

Biogen Inc. (NASDAQ:BIIB) Holdings Decreased by US Bancorp DE - MarketBeat

04:12 AM
pulisher
01:54 AM

Vanguard Group Inc's Strategic Acquisition of Biogen Inc Shares - GuruFocus.com

01:54 AM
pulisher
Nov 04, 2024

Biosimilars Market 2024-2031 Market Analysis: Growth Trends, Demand, and Forecast Overview | Biogen Idec Inc - EIN News

Nov 04, 2024
pulisher
Nov 04, 2024

Biogen (NASDAQ:BIIB) Price Target Cut to $210.00 by Analysts at JPMorgan Chase & Co. - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Biogen stock touches 52-week low at $173.01 amid market challenges - Investing.com Canada

Nov 04, 2024
pulisher
Nov 04, 2024

Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Wedbush Issues Negative Estimate for Biogen Earnings - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Biogen Analysts Slash Their Forecasts After Q3 Results - MSN

Nov 03, 2024
pulisher
Nov 02, 2024

Executive reshuffles: BIIB, USB and WES - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

New York State Teachers Retirement System Lowers Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso - Scrip

Nov 01, 2024
pulisher
Nov 01, 2024

Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch

Nov 01, 2024
pulisher
Nov 01, 2024

What is William Blair's Forecast for Biogen Q4 Earnings? - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Biogen, Eisai seek FDA nod for injectable Leqembi (BIIB:NASDAQ) - Seeking Alpha

Nov 01, 2024
pulisher
Nov 01, 2024

Rx Rundown: AbbVie, Biogen, GSK and more - MM+M Online

Nov 01, 2024
pulisher
Nov 01, 2024

Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Nov 01, 2024
pulisher
Nov 01, 2024

Eisai, Biogen eye 2025 approval for Leqembi autoinjector - pharmaphorum

Nov 01, 2024
pulisher
Oct 31, 2024

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status - StockTitan

Oct 31, 2024
pulisher
Oct 31, 2024

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status - Biogen | Investor Relations

Oct 31, 2024
pulisher
Oct 31, 2024

Roche weighs whether speedy approval path is open for latest Alzheimer’s drug - BioPharma Dive

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter (BIIB) - Seeking Alpha

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen Inc (BIIB) Trading Down 3.15% on Oct 31 - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen (NASDAQ:BIIB) Reaches New 1-Year LowShould You Sell? - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen's (BIIB) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen stock slips as Morgan Stanley downgrades (BIIB:NASDAQ) - Seeking Alpha

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen, Neomorph pact worth $1.45B for molecular glue degraders - BioWorld Online

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen Inc. (NASDAQ:BIIB) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024
pulisher
Oct 31, 2024

Recurrent Energy Announces Successful Operation of 134 MW Solar Project - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen shares target lifted by Piper Sandler as diversification strategy unfolds - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating R - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Diversify Advisory Services LLC Acquires Shares of 4,719 Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Morgan Stanley downgrades Biogen stock as Leqembi launch disappoints - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen Inc. Raises 2024 Financial Outlook Amid Product Launch Success - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Biogen/Eisai announce latest findings for Leqembi in Alzheimer’s disease - TipRanks

Oct 30, 2024
pulisher
Oct 30, 2024

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference - Biogen | Investor Relations

Oct 30, 2024
pulisher
Oct 30, 2024

Eisai Presents Data on Benefits of Long-Term Administration - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference – Company AnnouncementFT.com - Financial Times

Oct 30, 2024
pulisher
Oct 30, 2024

Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder - MedCity News

Oct 30, 2024
pulisher
Oct 30, 2024

Earnings call: Biogen reports progress and strategic pipeline expansion - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Goldman Sachs maintains Buy on Biogen with $290 target - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Biogen Announces CFO Transition and Regulation FD Update - TipRanks

Oct 30, 2024
pulisher
Oct 30, 2024

Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. - Investor's Business Daily

Oct 30, 2024
pulisher
Oct 30, 2024

Leqembi global sales hit $67M, but US adoption remains a challenge - FirstWord Pharma

Oct 30, 2024
pulisher
Oct 30, 2024

Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Biogen and Neomorph enter molecular glue degrader deal - Pharmaceutical Technology

Oct 30, 2024
pulisher
Oct 30, 2024

Biogen (BIIB) Q3 2024 Earnings Call Transcript - The Motley Fool

Oct 30, 2024
pulisher
Oct 30, 2024

Biogen Exceeds EPS Estimate, Revenue Declines - The Motley Fool

Oct 30, 2024
pulisher
Oct 30, 2024

Hints of impatience grow with Biogen as it tries to find a bridge to growth - Endpoints News

Oct 30, 2024

Biogen Inc Stock (BIIB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general BMY
$55.95
price up icon 0.90%
drug_manufacturers_general SNY
$52.85
price down icon 0.19%
drug_manufacturers_general PFE
$27.99
price up icon 0.83%
$319.29
price up icon 0.75%
drug_manufacturers_general NVS
$109.38
price down icon 1.03%
drug_manufacturers_general MRK
$101.65
price down icon 0.22%
Cap:     |  Volume (24h):